 CAMBRIDGE, Mass., July 31, 2020 GLOBE NEWSWIRE -- Jounce Therapeutics, Inc. NASDAQ: JNCE, a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report second quarter 2020 financial results and provide a corporate update before market open on Friday, August 7, 2020. Jounce Therapeutics management team will host a live conference call and webcast at 8:00 a.m. ET. Conference Call and Webcast To access the conference call, please dial 866 916-3380 domestic or 210 874-7772 international and refer to conference ID 3898328. The live webcast can be accessed under Events Presentations in the Investors and Media section of the companys website at The webcast will be archived and made available for replay on the companys website approximately two hours after the call and will be available for 30 days thereafter.About Jounce Therapeutics Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has four development-stage programs, two of which are clinical-stage: vopratelimab, a monoclonal antibody that binds to and activates ICOS, and JTX-4014, a PD-1 inhibitor intended for combination use with Jounces broader pipeline. Vopratelimab is currently being assessed in a Phase 2 clinical trial, EMERGE, and Jounce plans to initiate an additional Phase 2 biomarker trial using TISvopra for patient selection, SELECT, to assess vopratelimab in combination with JTX-4014. Jounces IND-enabling preclinical programs include JTX-8064, a LILRB2 receptor antagonist, and JTX-1811, a monoclonal antibody designed to selectively deplete T regulatory cells in the tumor microenvironment. For more information, please visit Contact: Komal Joshi Jounce Therapeutics, Inc. 857 320-2523 